File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jinf.2025.106426
- Scopus: eid_2-s2.0-85217119857
- PMID: 39864526
- Find via

Supplementary
- Citations:
- Appears in Collections:
Article: Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project
| Title | Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project |
|---|---|
| Authors | Yang, YangyupeiKnoll, Maria DeloriaHerbert, CarlyBennett, Julia C.Feikin, Daniel R.Garcia Quesada, MariaHetrich, Marissa K.Zeger, Scott L.Kagucia, Eunice W.Xiao, MelodyCohen, Adam L.van der Linden, Markdu Plessis, MignonYildirim, InciWinje, Brita A.Varon, EmmanuelleValenzuela, Maria TeresaValentiner-Branth, PalleSteens, AnnekeScott, J. AnthonySavrasova, LarisaSanz, Juan CarlosKhan, Aalisha SahuOishi, KazunoriNzoyikorera, NéhémieNuorti, J. PekkaMereckiene, JolitaMcMahon, KimberleyMcGeer, AllisonMackenzie, Grant A.MacDonald, LauraLadhani, Shamez N.Kristinsson, Karl G.Kleynhans, JackieKellner, James D.Jayasinghe, SanjayHo, Pak LeungHilty, MarkusHammitt, Laura L.Guevara, MarcelaGilkison, CharlotteGierke, RyanDesmet, StefanieDe Wals, PhilippeDagan, RonColzani, EdoardoCiruela, PilarChuluunbat, UrtnasanChan, GuanhaoCamilli, RominaBruce, Michael G.Brandileone, Maria Cristina C.Ampofo, KrowO'Brien, Katherine L.Hayford, Kyla |
| Keywords | Incidence Indirect protection Pneumococcal conjugate vaccines Pneumococcal meningitis Serotype replacement Serotypes Vaccine impact |
| Issue Date | 24-Jan-2025 |
| Publisher | W.B. Saunders. |
| Citation | The Journal of infection, 2025, v. 90, n. 3 How to Cite? |
| Abstract | Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited. |
| Persistent Identifier | http://hdl.handle.net/10722/368178 |
| ISSN | 2023 Impact Factor: 14.3 2023 SCImago Journal Rankings: 2.669 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yang, Yangyupei | - |
| dc.contributor.author | Knoll, Maria Deloria | - |
| dc.contributor.author | Herbert, Carly | - |
| dc.contributor.author | Bennett, Julia C. | - |
| dc.contributor.author | Feikin, Daniel R. | - |
| dc.contributor.author | Garcia Quesada, Maria | - |
| dc.contributor.author | Hetrich, Marissa K. | - |
| dc.contributor.author | Zeger, Scott L. | - |
| dc.contributor.author | Kagucia, Eunice W. | - |
| dc.contributor.author | Xiao, Melody | - |
| dc.contributor.author | Cohen, Adam L. | - |
| dc.contributor.author | van der Linden, Mark | - |
| dc.contributor.author | du Plessis, Mignon | - |
| dc.contributor.author | Yildirim, Inci | - |
| dc.contributor.author | Winje, Brita A. | - |
| dc.contributor.author | Varon, Emmanuelle | - |
| dc.contributor.author | Valenzuela, Maria Teresa | - |
| dc.contributor.author | Valentiner-Branth, Palle | - |
| dc.contributor.author | Steens, Anneke | - |
| dc.contributor.author | Scott, J. Anthony | - |
| dc.contributor.author | Savrasova, Larisa | - |
| dc.contributor.author | Sanz, Juan Carlos | - |
| dc.contributor.author | Khan, Aalisha Sahu | - |
| dc.contributor.author | Oishi, Kazunori | - |
| dc.contributor.author | Nzoyikorera, Néhémie | - |
| dc.contributor.author | Nuorti, J. Pekka | - |
| dc.contributor.author | Mereckiene, Jolita | - |
| dc.contributor.author | McMahon, Kimberley | - |
| dc.contributor.author | McGeer, Allison | - |
| dc.contributor.author | Mackenzie, Grant A. | - |
| dc.contributor.author | MacDonald, Laura | - |
| dc.contributor.author | Ladhani, Shamez N. | - |
| dc.contributor.author | Kristinsson, Karl G. | - |
| dc.contributor.author | Kleynhans, Jackie | - |
| dc.contributor.author | Kellner, James D. | - |
| dc.contributor.author | Jayasinghe, Sanjay | - |
| dc.contributor.author | Ho, Pak Leung | - |
| dc.contributor.author | Hilty, Markus | - |
| dc.contributor.author | Hammitt, Laura L. | - |
| dc.contributor.author | Guevara, Marcela | - |
| dc.contributor.author | Gilkison, Charlotte | - |
| dc.contributor.author | Gierke, Ryan | - |
| dc.contributor.author | Desmet, Stefanie | - |
| dc.contributor.author | De Wals, Philippe | - |
| dc.contributor.author | Dagan, Ron | - |
| dc.contributor.author | Colzani, Edoardo | - |
| dc.contributor.author | Ciruela, Pilar | - |
| dc.contributor.author | Chuluunbat, Urtnasan | - |
| dc.contributor.author | Chan, Guanhao | - |
| dc.contributor.author | Camilli, Romina | - |
| dc.contributor.author | Bruce, Michael G. | - |
| dc.contributor.author | Brandileone, Maria Cristina C. | - |
| dc.contributor.author | Ampofo, Krow | - |
| dc.contributor.author | O'Brien, Katherine L. | - |
| dc.contributor.author | Hayford, Kyla | - |
| dc.date.accessioned | 2025-12-24T00:36:41Z | - |
| dc.date.available | 2025-12-24T00:36:41Z | - |
| dc.date.issued | 2025-01-24 | - |
| dc.identifier.citation | The Journal of infection, 2025, v. 90, n. 3 | - |
| dc.identifier.issn | 0163-4453 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/368178 | - |
| dc.description.abstract | Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited. | - |
| dc.language | eng | - |
| dc.publisher | W.B. Saunders. | - |
| dc.relation.ispartof | The Journal of infection | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | Incidence | - |
| dc.subject | Indirect protection | - |
| dc.subject | Pneumococcal conjugate vaccines | - |
| dc.subject | Pneumococcal meningitis | - |
| dc.subject | Serotype replacement | - |
| dc.subject | Serotypes | - |
| dc.subject | Vaccine impact | - |
| dc.title | Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1016/j.jinf.2025.106426 | - |
| dc.identifier.pmid | 39864526 | - |
| dc.identifier.scopus | eid_2-s2.0-85217119857 | - |
| dc.identifier.volume | 90 | - |
| dc.identifier.issue | 3 | - |
| dc.identifier.issnl | 0163-4453 | - |
